• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection >Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.
【24h】

Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.

机译：头孢他啶或亚胺培南/西司他丁相对于头孢曲松钠+氨基糖苷在德国中性粒细胞减少症患者高热发作中的成本效益。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A three-pronged cost-effectiveness analysis of the treatment of febrile episodes in neutropenic cancer patients was conducted. It included a review of 37 randomized, controlled studies in the MEDLINE and EMBASE databases (1980-1996). Clinical outcomes as well as costs of treatment with imipenem/cilastatin, ceftazidime and ceftriaxone + aminoglycoside were compared. Primary therapy and modification, respectively, were successful in 62 and 27% of patients treated with imipenem/cilastatin, in 56 and 31% with ceftazidime and in 41 and 13% with ceftriaxone + aminoglycoside. From the perspective of a 1,800-bed teaching hospital, the average overall cost per successfully treated patient was DM 7,475 with imipenem/cilastatin, DM 7,810 with ceftazidime and DM 8,963 with ceftriaxone + netilmicin (DM 1 = USD 0.56; 7/97). The costs for the German national economy were imipenem/cilastatin DM 23,828, ceftazidime DM 24,985 and ceftriaxone + netilmicin DM 29,838.
机译：对中性粒细胞减少症患者的发热发作进行了三管齐下的成本效益分析。它包括对MEDLINE和EMBASE数据库中的37项随机对照研究的回顾（1980-1996年）。比较了亚胺培南/西司他丁，头孢他啶和头孢曲松钠+氨基糖苷的临床结局以及治疗费用。分别接受亚胺培南/西司他丁治疗的患者分别有62％和27％，使用头孢他啶治疗的患者分别占62％和27％，使用头孢他啶治疗的患者分别占56％和31％，使用头孢曲松钠+氨基糖苷治疗的患者分别占41％和13％。从拥有1,800张病床的教学医院的角度来看，每位成功接受治疗的患者的平均总费用为7,475马克（含亚胺培南/西司他丁），7,810 DM（含头孢他啶）和8,963 DM（含头孢曲松+奈替米星）（1 DM = 0.56美元; 7/97）。德国国民经济的损失为亚胺培南/西司他丁DM 23,828，头孢他啶DM 24,985和头孢曲松+奈替米星DM 29,838。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号